441 results on '"Roumenina, Lubka T."'
Search Results
52. Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside
53. C3‐dependent effector functions of complement.
54. Complement factor H: a guardian within?
55. Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody
56. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome
57. Heme: driver of erythrocyte elimination
58. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy
59. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis
60. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
61. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s
62. Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide
63. Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases
64. Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency
65. Complement factor H related proteins (CFHRs)
66. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions
67. Le complément intracellulaire C5a/C5aR1 stabilise la β-caténine pour favoriser la tumorigenèse colorectale.
68. C1q and its growing family
69. Anti-Factor H Autoantibodies Assay
70. Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS)
71. Interaction of Clq with IgGl, C-reactive protein and pentraxin 3: Mutational studies using recombinant globular head molecules of human Clq A, B, and C chains
72. Terminal complement without C5 convertase?
73. Role of Ca(super 2+) in the electrostatic stability and the functional activity of the globular domain of human Clq
74. The receptor for advanced glycation end products is a sensor for cell‐free heme
75. B cells and cancer: To B or not to B?
76. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
77. Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay
78. Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme
79. Adult post COVID-19 multisystem inflammatory syndrome and thrombotic microangiopathy
80. Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis
81. Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation
82. The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression
83. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy
84. Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit
85. The receptor for advanced glycation end products is a sensor for cell‐free heme.
86. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction
87. Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency
88. Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth
89. Autoantibodies Against C3b—Functional Consequences and Disease Relevance
90. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1
91. Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H
92. A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein
93. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy
94. ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE
95. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles
96. Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis
97. Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum
98. Complement C3 is a novel modulator of the anti-factor VIII immune response
99. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies
100. Existence of different but overlapping IgG- and IgM-binding sites on the globular domain of human C1q
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.